Seminars in Oncology
Volume 35, Issue 6 , Pages 643-651 , December 2008

Cancer Therapy and Osteoporosis: Approach to Evaluation and Management

  • G.J. van Londen

      Affiliations

    • Department of Medicine, Divisions of Geriatrics and Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA
    • ,
  • Pamela Taxel

      Affiliations

    • Departments of Medicine, Division of Endocrinology and Metabolism, University of Connecticut Health Center, Farmington, CT
    • ,
  • Catherine Van Poznak

      Affiliations

    • University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
    • Corresponding Author InformationAddress correspondence to Catherine Van Poznak, MD, University of Michigan Comprehensive Cancer Center, 1500 E Medical Center Dr, C346 Med Inn Building, Ann Arbor MI 48109

References 

  1. Physician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003;www.nof.orgaccessed July 5, 2008
  2. Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom. 2006;9:4–14
  3. Melton LJ, Riggs BL. Epidemiology of age-related fractures. In:  Avioli LV editors. The osteoporotic syndrome. New York: Grune & Stratton; 1983;p. 45–72
  4. Hadjidakis DJ, Androulakis . Bone remodeling. Ann N Y Acad Sci. 2006;1092:385–396
  5. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318–3325
  6. Taxel P, Fall PM, Albertsen PC, Dowsett RD, Trahiotis M, Zimmerman J, et al. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:4907–4913
  7. Meier C, Nguyen TV, Handelsman DJ, Schindler C, Kushnir MM, Rockwood AL, et al. Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168:47–54
  8. Mellström D, Vandenput L, Mallmin H, Holmberg AH, Lorentzon M, Oden A, et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res. Epub ahead of print June 2. 2008;18518773
  9. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726–1733
  10. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  11. Rosen CJ. Clinical practice (Postmenopausal osteoporosis). N Engl J Med. 2005;353:595–603
  12. Ebeling PR. Clinical practice (Osteoporosis in men). N Engl J Med. 2008;358:1474–1482
  13. National Osteoporosis Foundation. http://www.nof.org/osteoporosis/diseasefacts.htmaccessed July 5, 2008
  14. Wachtel TJ. Geriatric osteoporosis. Med Health R I. 2007;90:330–333
  15. Andersen SJ. Osteoporosis in the older woman. Clin Obstet Gynecol. 2007;50:752–766
  16. Preventing falls among older adults. CDC. http://www.cdc.gov/ncipc/factsheets/adultfalls.htmaccessed July 5, 2008
  17. Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Jarvinen M, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med. 2000;343:1506–1513
  18. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: a systematic review. BMJ. 2006;332:571–574
  19. Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med. 2005;353:164–171
  20. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry. JAMA. 2002;288:1889–1897
  21. Wilkins CH, Birge SJ. Prevention of osteoporotic fractures in the elderly. Am J Med. 2005;118:1190–1195
  22. Optimal calcium intake. NIH Consensus Statement. June 6-8 1994;12(4):1-31.
  23. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999;281:1505–1511
  24. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf). 2005;62:265–281
  25. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004;291:1999–2006
  26. Avenell A, Gillespie WJ, Gillespie LD, O'Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev. 2005;(3):CD000227
  27. Kantor SM, Ossa KS, Hoshaw-Woodard SL, Lemeshow S. Height loss and osteoporosis of the hip. J Clin Densitom. 2004;7:65–70
  28. Green AD, Colon-Emeric CS, Bastian L, Drake MT, Lyles KW. Does this woman have osteoporosis?. JAMA. 2004;292:2890–2900
  29. Rosen CJ. Clinical practice (Postmenopausal osteoporosis). N Engl J Med. 2005;353:595–603
  30. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int. 2005;16:713–716
  31. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185–1194
  32. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108–1112
  33. US Preventive Services Task Force. Clinical guidelines: screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002;137:526–528
  34. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042–4057
  35. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis. 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9:544–564
  36. Lewiecki EM, Richmond B, Miller PD. Uses and misuses of quantitative ultrasonography in managing osteoporosis. Cleve Clin J Med. 2006;73:742–746
  37. Genant HK, Jiang Y. Advanced imaging assessment of bone quality. Ann N Y Acad Sci. 2006;1068:410–428
  38. Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?. Bone. 2007;41:308–317
  39. Small W, Kachnic L. Postradiotherapy pelvic fractures: cause for concern or opportunity for future research?. JAMA. 2005;294:2635–2637
  40. Greep NC, Giuliano AE, Hansen NM, Taketani T, Wang HJ, Singer FR. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med. 2003;114:653–659
  41. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18:1570–1593
  42. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med. 1992;326:852–856
  43. Lin NU, Winer EP. Advances in endocrine therapy for postmenopausal women. J Clin Oncol. 2008;26:798–805
  44. Van Pottelbergh I, Goemaere S, Kaufman JM. Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab. 2003;88:3075–3081
  45. Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res. 2006;12:6315s–6319s
  46. Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea MA, Owens DK. Clinical Efficacy Assessment Subcommittee American College of Physicians. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;148:680–684
  47. Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab. 2001;86:5681–5685
  48. American College of Rheumatology Ad Hoc Committee on Glucocorticoid Induced Osteoporosis. Recommendations for the prevention and treatment of glucocoriticoid induced osteoporosis. Arthritis Rheum. 2001;44:1496–1503
  49. Heffernan MP, Saag KG, Robinson JK, Callen JP. Prevention of osteoporosis associated with chronic glucocorticoid therapy. JAMA. 2006;295:1300–1303
  50. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008;19:420–432
  51. Holmberg L, Anderson H. HABITS Steering and Data Monitoring Committees. HABITS (Hormonal Replacement Therapy After Breast Cancer–Is It Safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–455
  52. O'Regan RM, Gajdos C, Dardes RC, De Los Reyes A, Park W, Rademaker AW, et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst. 2002;94:274–283
  53. Van Poznak C, Sauter NP. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer. 2005;104:443–456
  54. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004;100:892–899
  55. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–1046
  56. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60–62
  57. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349:1793–1802
  58. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  59. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119–127
  60. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–2757
  61. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25:486–492
  62. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol. 2005;23:5138–5147
  63. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005;366:455–462
  64. Ellis G, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, et al. A phase 3 study of the effect of denosumab therapy on bone mineral density in women receiving aromatase inhibitors for non metastatic breast cancer [abstract]. Breast Cancer Res Treat. 2007;106:47
  65. Lester J, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, et al. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: two-year results from the ARIBON study [abstract]. J Clin Oncol. 2008;26:554
  66. Greenspan SL, Brufsky A, Lembersky BC, Bhattacharya R, Vujevich KT, Perera S, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol. 2008;26:2644–2652
  67. Van Poznak C, Hannon RA, Clack G, Campone M, Mackey JR, Apffelstaedt J, et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis [abstract 502]. Breast Cancer Res Treat. 2007;106:S37
  68. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–836
  69. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med. 2007;146:416–424
  70. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med. 2001;345:948–955
  71. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer. 2001;92:1444–1450
  72. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:3841–3846
  73. Taxel P, Dowsett R, Albertsen P, Fall P, Biskup B, Raisz LG. Risedronate prevents early bone loss and increased turnover in men receiving LHRH-agonist therapy for prostate cancer. J Bone Miner Res. 2006;Suppl 1:SU062
  74. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179:152–155
  75. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–2012

 C.V.P. has served as consultant for Amgen (12/07) and Roche (12/06).

PII: S0093-7754(08)00191-7

doi: 10.1053/j.seminoncol.2008.08.008

Seminars in Oncology
Volume 35, Issue 6 , Pages 643-651 , December 2008

Article Tools

* Image Usage & Resolution